Ke-Ita Tatsumi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ke-Ita Tatsumi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Nobuyuki Amino
Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita, Japan
4 shared publicationsHirokazu Fujiwara
Department of Laboratory Medicine, Osaka University Graduate School of Medicine, Suita, Japan
2 shared publicationsKiyoshi Miyai
2 shared publications- Susumu Tanaka
Department of Nutrition Science, University of Nagasaki, Siebold, Nagasaki 851-2195, Japan
2 shared publications H. Yoshikawa
1 shared publicationKazunori Miki
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 57 (11) , 997-999
Characterization of Thr-354 in the human sodium/iodide symporter (NIS) by site-directed mutagenesis
Sodium/iodide symporter (NIS) is the key molecule concentrating iodide in the thyroid gland. The first-described human NIS (hNIS) mutation to cause a complete iodide transport defect was the T354P mutation. The Thr-354 lies in the midst of the putative ninth transmembrane segment which is well-conserved within the members of the SLC5A transporter family. Here we have investigated the molecular function of Thr-354 using site-directed mutagenesis and found that T354S and T354A mutations result in significantly decreased iodide transport activity, 50 % and 2 % of wild-type hNIS. Our findings indicate that whereas Thr-354 is indispensable for the complete NIS activity, the β-hydroxyl group accounts for half, and the α-helical structure alone contributes for one-fiftieth of wild-type hNIS activity.
- 1 January 2010
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 57 (11) , 997-999
Open AccessCharacterization of Thr-354 in the human sodium/iodide symporter (NIS) by site-directed mutagenesis
Sodium/iodide symporter (NIS) is the key molecule concentrating iodide in the thyroid gland. The first-described human NIS (hNIS) mutation to cause a complete iodide transport defect was the T354P mutation. The Thr-354 lies in the midst of the putative ninth transmembrane segment which is well-conserved within the members of the SLC5A transporter family. Here we have investigated the molecular function of Thr-354 using site-directed mutagenesis and found that T354S and T354A mutations result in significantly decreased iodide transport activity, 50 % and 2 % of wild-type hNIS. Our findings indicate that whereas Thr-354 is indispensable for the complete NIS activity, the β-hydroxyl group accounts for half, and the α-helical structure alone contributes for one-fiftieth of wild-type hNIS activity.
- 1 November 2004
- Published by Wiley in Clinical Endocrinology
- Vol. 61 (5) , 635-640
A novel PROP1 gene mutation (157delA) in Japanese siblings with combined anterior pituitary hormone deficiency
The majority of cases of combined anterior pituitary hormone deficiency (CPHD) reported in Japanese patients have PIT1 abnormality. This study describes for the first time a homozygous mutation of the PROP1 gene in two Japanese siblings with CPHD born to consanguineous parents. Two siblings were growth retarded at 3 years of age and developed hypothyroidism. Pituitary function tests showed combined deficiency of GH, TSH, PRL and gonadotrophins. The size of their pituitary glands decreased with age, as demonstrated by magnetic resonance imaging (MRI). The PROP1 gene was analysed by polymerase chain reaction (PCR) followed by direct sequencing. Both children were homozygous for a novel single base deletion at codon 53 (157delA), while their parents were heterozygous. This mutation, if translated, predicts the production of a protein lacking the paired-like homeodomain required for DNA binding, suggesting that the mutation was the direct cause of CPHD in these patients. 157delA is the first reported Japanese PROP1 gene mutation. In Japan, PROP1 abnormality appears to be a less frequent cause of CPHD than does PIT1 abnormality, whereas PROP1 abnormality predominates in CPHD patients of Caucasian and European origin.
- 1 November 2004
- Published by Wiley in Clinical Endocrinology
- Vol. 61 (5) , 635-640
A novel PROP1 gene mutation (157delA) in Japanese siblings with combined anterior pituitary hormone deficiency
The majority of cases of combined anterior pituitary hormone deficiency (CPHD) reported in Japanese patients have PIT1 abnormality. This study describes for the first time a homozygous mutation of the PROP1 gene in two Japanese siblings with CPHD born to consanguineous parents. Two siblings were growth retarded at 3 years of age and developed hypothyroidism. Pituitary function tests showed combined deficiency of GH, TSH, PRL and gonadotrophins. The size of their pituitary glands decreased with age, as demonstrated by magnetic resonance imaging (MRI). The PROP1 gene was analysed by polymerase chain reaction (PCR) followed by direct sequencing. Both children were homozygous for a novel single base deletion at codon 53 (157delA), while their parents were heterozygous. This mutation, if translated, predicts the production of a protein lacking the paired-like homeodomain required for DNA binding, suggesting that the mutation was the direct cause of CPHD in these patients. 157delA is the first reported Japanese PROP1 gene mutation. In Japan, PROP1 abnormality appears to be a less frequent cause of CPHD than does PIT1 abnormality, whereas PROP1 abnormality predominates in CPHD patients of Caucasian and European origin.
- Open Access
- 1 February 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (2) , 353-356
Novel autoantibodies to pituitary gland specific factor 1a in patients with rheumatoid arthritis
Objective. We recently identified a new protein, pituitary gland specific factor 1a (PGSF1a), that is specifically transcribed in the pituitary gland. In our investigation of anti‐PGSF1a antibody for pituitary diseases, we examined it in patients with RA and other autoimmune diseases. We unexpectedly discovered the frequent existence of anti‐PGSF1a antibody in patients with RA. We therefore examined the prevalence of this antibody to understand its clinical significance in RA. Methods. Anti‐PGSF1a antibody was detected by radioligand assay using recombinant 35S‐labelled PGSF1a protein. Antibody activity is expressed as an index that was obtained by comparison with normal pooled serum. Results. RA patients had a significantly higher mean anti‐PGSF1a antibody index (n=46, 1.28±0.38, P < 0.001) than healthy controls (n=36, 1.04±0.13). Indices greater than the cut‐off value (mean+2 s.d. of healthy controls) were found in 43.5% (20/46) and 10.0% (2/20) of patients with RA and osteoarthritis, respectively. There was no correlation between the activities of anti‐PGSF1a antibodies and titres of rheumatoid factor (RF) or serum C‐reactive protein concentrations, but RA patients with more erosive disease had a higher mean anti‐PGSF1a antibody index. Four of eight sera samples obtained from RF‐negative RA patients were positive for anti‐PGSF1a antibodies. Conclusion. Anti‐PGSF1a antibody is a useful new marker for the diagnosis of RA, especially for RF‐negative RA, and may relate to clinical manifestations of RA.
- 1 February 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (2) , 353-356
Open AccessNovel autoantibodies to pituitary gland specific factor 1a in patients with rheumatoid arthritis
Objective. We recently identified a new protein, pituitary gland specific factor 1a (PGSF1a), that is specifically transcribed in the pituitary gland. In our investigation of anti‐PGSF1a antibody for pituitary diseases, we examined it in patients with RA and other autoimmune diseases. We unexpectedly discovered the frequent existence of anti‐PGSF1a antibody in patients with RA. We therefore examined the prevalence of this antibody to understand its clinical significance in RA. Methods. Anti‐PGSF1a antibody was detected by radioligand assay using recombinant 35S‐labelled PGSF1a protein. Antibody activity is expressed as an index that was obtained by comparison with normal pooled serum. Results. RA patients had a significantly higher mean anti‐PGSF1a antibody index (n=46, 1.28±0.38, P < 0.001) than healthy controls (n=36, 1.04±0.13). Indices greater than the cut‐off value (mean+2 s.d. of healthy controls) were found in 43.5% (20/46) and 10.0% (2/20) of patients with RA and osteoarthritis, respectively. There was no correlation between the activities of anti‐PGSF1a antibodies and titres of rheumatoid factor (RF) or serum C‐reactive protein concentrations, but RA patients with more erosive disease had a higher mean anti‐PGSF1a antibody index. Four of eight sera samples obtained from RF‐negative RA patients were positive for anti‐PGSF1a antibodies. Conclusion. Anti‐PGSF1a antibody is a useful new marker for the diagnosis of RA, especially for RF‐negative RA, and may relate to clinical manifestations of RA.
- 1 August 1998
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 36 (8) , 659-662
Genetic Basis of Congenital Hypothyroidism: Abnormalities in the TSHβ Gene, the PIT1 Gene, and the NIS Gene
We have elucidated the molecular pathology of three types of congenital hypothyroidism. Thyrotropin (TSH) is the major regulator of thyroid function. In cases of isolated congenital TSH deficiency, we found that they are caused by a missense mutation in the conserved CAGYC region of the TSHβ gene. Pit-1/GHF-1 is a pituitary specific POU-domain DNA binding factor, which transactivates the growth hormone (GH), prolactin (PRL), TSHβ genes, and the PIT1 gene itself. In cases of combined deficiency of GH, PRL, and TSH, we found that they are caused by abnormalities in the PIT1 gene, either recessively or dominantly. Sodium dependent iodide symporter (NIS) actively transports iodide into the thyroid cells to produce thyroid hormones. In cases of iodide transport defect, we elucidated that a missense mutation in the transmembrane region of the NIS gene caused them.
- 1 August 1998
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 36 (8) , 659-662
Genetic Basis of Congenital Hypothyroidism: Abnormalities in the TSHβ Gene, the PIT1 Gene, and the NIS Gene
We have elucidated the molecular pathology of three types of congenital hypothyroidism. Thyrotropin (TSH) is the major regulator of thyroid function. In cases of isolated congenital TSH deficiency, we found that they are caused by a missense mutation in the conserved CAGYC region of the TSHβ gene. Pit-1/GHF-1 is a pituitary specific POU-domain DNA binding factor, which transactivates the growth hormone (GH), prolactin (PRL), TSHβ genes, and the PIT1 gene itself. In cases of combined deficiency of GH, PRL, and TSH, we found that they are caused by abnormalities in the PIT1 gene, either recessively or dominantly. Sodium dependent iodide symporter (NIS) actively transports iodide into the thyroid cells to produce thyroid hormones. In cases of iodide transport defect, we elucidated that a missense mutation in the transmembrane region of the NIS gene caused them.
- 1 June 1997
- Published by Springer Nature in Nature Genetics
- Vol. 16 (2) , 124-125
Congenital hypothyroidism caused by a mutation in the Na+/l− symporter
- 1 June 1997
- Published by Springer Nature in Nature Genetics
- Vol. 16 (2) , 124-125
Congenital hypothyroidism caused by a mutation in the Na+/l− symporter